|
Balaji, V., P. Rupali, K. Walia, et al.
Indian Council of Medical Research
(2018)
C2
|
|
|
National Department of Health South Africa
(2019)
C1
|
|
|
|
|
|
Federal Democratic Republic of Ethiopia -Ministry of Health
(2018)
C1
|
|
|
Rajiha A. Ibrahim, Amete M. Teshal, Surafel F. Dinku, et al.
(2018)
CC
African Journal of Laboratory Medicine | Vol 7, No 2 | a770 | 06 December 2018
|
|
|
The Center for Disease Dynamics, Economics & Policy CDDEP
(2017)
C2
|
|
|
National Centre for Disease Control; Ministry of Health & Family Welfare India
(2016)
C1
|
|
|
The Center for Disease Dynamics, Economics & Policy CDDEP
(2016)
C2
Pakistan Global Antibiotic Resistance Partnership (GARP) was formed in the wake of international and national efforts for AMR curtailment. A group of experts from microbiology, infectious diseases and veterinary medicine formed a core group at the organizational meeting of GARP in Kathmandu, Nepal in July 2016. In the meeting, this core group was expanded to include other members from different sectors with the selection of the Chair and co-chairs. These were asked to serve on a voluntary basis, in their own individual capacities, with no personal gains, or gains to the institutions to which they are affiliated. The first phase of GARP took place from 2009 to 2011 and involved four countries: India, Kenya, South Africa and Vietnam. Phase one culminated in the 1st Global Forum on Bacterial Infections, held in October 2011 in New Delhi, India. In 2012, phase two of GARP was initiated with the addition of working groups in Mozambique, Tanzania, Nepal and Uganda. Phase three has added Bangladesh, Lao PDR, Nigeria, Pakistan and Zimbabwe to the network to date ... more
|
|
|
COLL-SECK, A. M. ; I. SECK; A. IYANE SOW ; et al.
(2016)
C2
La résistance à un antimicrobien survient quand un micro-organisme (bactérie, virus, champignon ou parasite), devient résistant à un médicament antimicrobien vis-à-vis duquel il était auparavant sensible . Cette résistance aux antimicrobiens (RAM), concerne un large éventail d’agents infectieux, et de nombreux secteurs d’activités (santé humaine et animale, agro-industrie, élevage, environnement). Elle représente une menace croissante pour la santé publique et aucun pays n’est épargné. Il est particulièrement alarmant de constater la propagation rapide, dans le monde entier, des bactéries multirésistantes provoquant des infections courantes qui ne sont pas sensibles aux traitements antibiotiques habituellement utilisés, ainsi que des infections en particulier hospitalières, résistantes aux traitements antibiotiques de dernier recours . Le problème se pose actuellement en termes de développement durable : il dépasse largement le cadre de la santé humaine et interpelle le monde entier
AMR CONTROL – ÉDITION FRANÇAISE VOL. ... more
|
|
|
Dr Brink A. J., MD A P Messina, BPharm Prof C. Feldman, et al.
(2016)
C2
|
|